Ziftomenib is a small molecule commercialized by Kura Oncology, with a leading Phase II program in Relapsed Acute Myeloid Leukemia. According to Globaldata, it is involved in 5 clinical trials, of which 3 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Ziftomenib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Ziftomenib is expected to reach an annual total of $138 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Ziftomenib Overview

Ziftomenib (KO-539) is under development for the treatment of MLL- rearranged leukemias including NPM1 mutant or DNMT3A mutant refractory/relapsed acute myelocytic leukemia and adult and pediatric acute lymphoblastic leukemia. The drug candidate is administered orally as a capsule. It targets menin-MLL protein interaction.

Kura Oncology Overview

Kura Oncology is a biopharmaceutical company that discovers and develops therapeutics for the treatment of solid tumors and blood cancers. The company’s lead drug candidate Tipifarnib, an inhibitor of farnesyl transferase, an oral investigational drug candidate intended for the treatment of various types of cancer including HRAS mutant head and neck cancer, peripheral T-cell lymphomas, myelodysplastic syndromes and chronic myelomonocytic leukemia. Its other candidates include KO-947, an investigational drug candidate for mitogen-activated protein kinase pathway tumors and KO-539, a small molecule inhibitor for the treatment of acute leukemia. Kura Oncology is headquartered in San Diego, California, the US.

The operating loss of the company was US$139.9 million in FY2022, compared to an operating loss of US$131.5 million in FY2021. The net loss of the company was US$135.8 million in FY2022, compared to a net loss of US$130.5 million in FY2021.

For a complete picture of Ziftomenib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.